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Abstract
Background: Herpes Simplex Virus Type 2 (HSV-2) is highly prevalent in regions disproportionately affected by the
human immunodeficiency virus (HIV-1) epidemic. The objective of our study was to identify the risk factors of HSV-2
and HIV-1 infections and to examine the association between the two infections.
Methods: The study participants were recruited through a community based cross-sectional study that was
conducted from November 2002 to March 2003 in the Moshi urban district of Northern Tanzania. A two-stage
sampling design was used in recruiting the study participants. Information on socio-demographics, alcohol use,
sexual behaviors, and STIs symptoms were obtained. Blood and urine samples were drawn for testing of HIV-1,
HSV-2 and other STIs.
Results: The prevalence of HSV-2 infection among all study participants was 43%. The prevalence rate of HSV-2
among the HIV-negative and HIV-positive women was 40% and 65%, respectively. We found 2.72 times odds of
having HIV-1 in an HSV-2 positive woman than in an HSV-2 negative woman. Furthermore, HIV-1 and HSV-2 shared
common high-risk sexual behavior factors such as early onset of sexual debut, and testing positive for other STIs.
Conclusions: Our findings suggest that HSV-2 may be both a biological and risk-associated cofactor for HIV-1
acquisition. In resource-limited countries, where both infections are prevalent efforts at symptomatic and diagnostic
screening and treatment of HSV-2 should be part of HIV-1 prevention programs.
Background
The correlate of herpes simplex type 2 (HSV-2) and human
immunodeficiency virus type 1 (HIV-1) epidemics is intri-
guing and has been the subject of several studies. HSV-2 is
a common infection, with an estimated prevalence and inci-
dence of 536 and 23.6 million infections, respectively, in
15 – 49-year-olds worldwide [1]. HSV-2 infection is highly
prevalent in regions disproportionately affected by the
HIV-1 epidemic. Several epidemiological studies have
demonstrated higher incidence and prevalence rates of
HIV-1 among HSV-2-infected populations and vice versa
[2-5]. Sub-Saharan Africa with the highest prevalence of
HIV-1 has about 80% prevalence rate of HSV-2 among its
adult population [6,7]. The prevalence of HSV-2 in HIV-
infected individuals in sub-Saharan Africa is 50 to 90% [8].
Furthermore, there is a high seroprevalence of HSV-2 in
communities with high incidence of HIV-1 in developed
countries [9,10]. The similarities between the two infections
with regard to prevalence rates, risk factors, and geograph-
ical distribution cannot be a mere coincidence. If the asso-
ciation between HSV-2 infection and HIV-1 is causal, then
the proportion of HIV infections attributable to HSV-2 in-
fection is high, estimated at 25% –35% in sub-Saharan
Africa [11]. Thus, the high prevalence of HSV-2 and its
interaction with HIV-1 might have played a significant role
in the HIV-1 epidemic in sub-Saharan Africa.
Several epidemiological and laboratory studies have sug-
gested a biological plausibility of HSV-2 infection facilitat-
ing the acquisition and transmission of HIV-1. Recurrent
episodes of HSV-2 may increase the susceptibility to HIV-1
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target cells in the genital tract [8,12,13]. In HIV-1-
serodiscordant couples, HSV-2-seropositive individuals
were at increased risk of acquiring HIV-1 [14,15]. In indivi-
duals with HIV-1 and HSV-2 co-infection, symptomatic
and asymptomatic reactivation of HSV-2 has been asso-
ciated with increased plasma HIV-1 viral load and genital
shedding of HIV-1 [16]. To establish a relationship be-
tween HSV-2 and HIV-1 replication, several randomized
controlled trails have tested the effect of HSV-2 suppres-
sive therapy on HIV-1 transmission [14,17-20]. Unfortu-
nately, the effect of HSV-2 suppressive therapy - with
acyclovir - on HIV-1 transmission in these studies has been
mixed. However, most of these studies demonstrated a re-
duction in plasma and genital HIV-1 RNA concentrations
in co-infected individuals. Acyclovir, used in these trials,
has direct anti-HIV effect by inhibiting HIV-1 reverse tran-
scriptase [21,22]. Therefore, it has been argued that the
modest effect on HIV replication seen in these trials may
not be directly related to HSV-2-HIV-1 interaction. More-
over, the mixed reports might be due to the rather complex
nature of the interaction between the two pathogens and
the fact that both epidemics have matured and reached sat-
uration making it difficult to tease out the relationship by
clinical trials.
We hypothesized that HSV-2 epidemic might have con-
tributed to the evolution of the HIV epidemic in sub-
Saharan Africa. To test this hypothesis, we used data from
a community-based survey in the Moshi urban district of
northern Tanzania. The prevalence of HSV-2 in Tanzania
is estimated at 70% [23]. However, in the study cohort, the
prevalence of HSV-2 and HIV-1 are 43% and 11%, re-
spectively [24]. The objectives of our study were: 1) to
identify shared-risk factors of HSV-2 and HIV-1 infections
and 2) to examine the association between HIV-1 and
HSV-2 among study participants.
Methods
Study design
A detailed description of the study design and characteris-
tics of the study participants has been described previously
[24]. In brief, the study participants were recruited
through a community based cross-sectional study that
was conducted from November 2002 to March 2003 in
the Moshi urban district of Northern Tanzania. A two-
stage sampling design was used in recruiting the study
participants. First, 150 geographic clusters were randomly
selected from Moshi and then a number of households
were randomly selected from each cluster. A total of 2019
women who were residents of the households and 794
men who were their partners were enrolled into the study.
The participants’ socio-demographic, high-risk behavior,
biological, and medical characteristics were assessed. The
study was approved by the Harvard School of Public
Health IRB (HSC Protocol #0108ACOM), University of
Maryland IRB (Protocol #05-0031), Kilimanjaro Christian
Medical Center Ethics Committee, Research and Ethical
Clearance of the Tanzanian National Institute for Medical
Research, the Centers for Disease Control and Prevention
Institutional Review Board. Written informed consent for
participation in the study was obtained from participants.
Laboratory methods
Blood and urine samples were collected and tested for
HIV-1, HSV-2 and other sexually transmitted infections
(STIs). HIV-1 infection was determined using HIV
enzyme-linked immunosorbent assay (ELISA) (Vironos-
tika HIV Uni-Form II Plus O, Organon, Boxtel, The
Netherlands) and reactive samples were confirmed using
Wellcozyme HIV-1 ELISA test (Murex 1.2.0, Murex Bio-
tech Ltd., UK). Western blot tests (Bio-Rad Laboratories
Ltd., Dartford, UK) were used to confirm discordant
ELISA test results. Antibodies to HSV-2 were detected
using enzyme immune assay (EIA) according to the
manufacturer’s instructions (HerpeSelect 2 ELISA, Focus
Technologies, Cypress, CA). Active and past syphilis
were diagnosed if the serum was reactive on the Rapid
Plasma Reagin card test (Macro-Vue; Becton-Dickinson,
Cockeysville, MD) and/or the Treponema Pallidum
xHemagglutination Assay (TPHA) (Wecosyph HA;
Murex Bio-tech Ltd., UK). Urine samples were tested for
Chlamydia, gonorrhea, trichomonas and mycoplasma
genitalium by using a real-time multiplex polymerase
chain reaction (M-PRC) assay.
Study measures
Socio-demographic characteristics (e.g., age in years, re-
ligion, ethnicity, education), high-risk behaviors (e.g., age
at first sex, number of sexual partners in the previous
three years, alcohol use, condom use), and biological/
medical factors (e.g., circumcision, symptoms of STIs
and STIs other than HIV-1/HSV-2) were considered as
covariates in our analyses. Alcohol abuse was measured
by the CAGE score. An STI’s symptom was defined as
having at least one of the following symptoms: abdom-
inal pain, abnormal genital discharge, foul smell in the
genital area, excessive genital secretions, swellings in the
genital area, itching in the genital area, burning pain on
micturition, pain during intercourse, and genital ulcers.
Statistical methods
We have a clustered binary data with individuals (level-1),
i.e., women, nested in geographic clusters (level-2). It is rea-
sonable to assume that measurements from individuals
within the same cluster were correlated. Because of the in-
herent intra-cluster correlation between binary outcomes,
statistical modelling of the data using the ordinary logistic re-
gression is not appropriate. Therefore, multilevel generalized
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medical factors among women in Moshi district, northern Tanzania
Variables HSV-2 (N=1418) HIV-1 (N=1418)
Negative N (%) Positive N (%) P-value Negative N (%) Positive N (%) P-value
Age <0.01 0.04
20-24 354 (44) 99 (16) 419 (33) 34 (22)
25-29 205 (25) 140 (23) 303 (24) 42 (27)
30-34 119 (15) 140 (23) 228 (18) 31 (20)
35-39 78 (10) 120 (20) 168 (13) 30 (20)
≥ 40 52 (6) 109 (18) 144 (12) 17 (11)
Ethnicity 0.18 0.56
Chaga 438 (54) 301 (49) 665 (53) 74 (48)
Pare 98 (12) 77 (13) 154 (12) 21 (14)
Other 272 (34) 231 (38) 44 4(35) 59 (38)
Religion 0.05 0.54
Muslim/other 255 (32) 229 (38) 430 (34) 54 (35)
Catholic 332 (41) 237 (39) 503 (40) 66 (43)
Protestant 221 (27) 143 (23) 330 (26) 34 (22)
Education 0.52 0.34
Pre-secondary 622 (77) 477 (78) 975 (77) 124 (81)
Secondary and above 187 (23) 132 (22) 289 (23) 30 (19)
Alcohol abuse 0.71 0.82
No 296 (84) 291 (85) 508 (85) 79 (84)
Yes 55 (16) 50 (15) 90 (15) 15 (16)
Number of partners† 0.26 <0.01
1 587 (90) 492 (88) 967 (91) 112 (79)
2+ 64 (10) 66 (12) 100 (9) 30 (21)
Age at first sex <0.01 <0.01
<18 222 (28) 248 (42) 392 (32) 78 (52)
18-19 215 (27) 159 (27) 339 (27) 35 (23)
20+ 353 (45) 188 (31) 503 (41) 38 (25)
Condom use{ 0.85 0.27
Never 500 (77) 429 (77) 826 (78) 103 (75)
Sometimes 133 (21) 115 (21) 218 (20) 30 (22)
Often/always 11 (2) 12 (2) 18 (2) 5 (3)
Female circumcision 0.06 0.98
No 624 (77) 442 (73) 950 (75) 116 (75)
Yes 185 (23) 166 (27) 313 (25) 38 (25)
Test positive STIs* <0.01 <0.01
Negative 715 (88) 500 (82) 1098 (87) 117 (76)
Positive 94 (12) 109 (18) 166 (13) 37 (24)
STIs Symptoms 0.06 0.04
No 498 (71) 392 (66) 797 (70) 93 (62)
Yes 204 (29) 201 (34) 347 (30) 58 (38)
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the risk factors for both infections and the interplay be-
tween them. The correlation among individuals from the
same cluster was incorporated using a random intercept
at the cluster level. Measurements from individuals within
the same cluster were assumed to be independent given
the random intercept. Model parameters were estimated
via maximum likelihood based on adaptive quadrature
[25]. The analysis was performed using the GLIMMIX
procedure in SAS [26].
Results
Characteristics of study participants by their HSV-2 and
HIV-1 status
Among the 1418 women who provided blood samples,
154 and 609 were seropositive for HIV-1 and HSV-2, re-
spectively. The prevalence rate of HSV-2 among the
women who tested positive for HIV-1 was 65%, which
was 1.63 times higher than the rate of HSV-2 in women
who tested negative for HIV-1. Preliminary analysis was
done using Pearson’s Chi-square and Fisher’s exact tests
to identify the potential risk factors of HSV-2 and HIV-1
infections (Table 1). Table 1 presents participants’ socio-
demographic, risk behavior and medical/biological char-
acteristics by their HSV-2 and HIV-1 infection status.
The prevalence of both HSV-2 (p<0.01) and HIV-1
(p=0.04) was significantly associated with the age of the
participant. Religion was significantly associated with
HSV-2 (p=0.05) but not with HIV-1 (p=0.54). HSV-2
prevalence rate was lower for Protestants compared to
that of the other religions/denominations. Number of
sexual partners in the previous three years was asso-
ciated with HIV-1 (p<0.01) but not with HSV-2
(p=0.26). HSV-2 and HIV-1 prevalence rates were sig-
nificantly associated with age at first sex (p<0.01), with
higher rates among women who experienced an early
sexual debut. That is, postponing age at first sexual
debut was protective for both infections. Having a posi-
tive test for STI (e.g., syphilis, chlamydia, gonorrhea, tri-
chomonas and mycoplasma genitalium) was significantly
associated with HSV-2 and HIV-1 status (p<0.01).
There was a significant association between having
symptoms of STIs at study enrolment and HIV-1 status
(p=0.04). However, the association between symptoms
of STIs and HSV-2 status was only marginally significant
(p=0.06). HSV-2 status was significantly associated with
HIV-1 status (p<0.01). Female circumcision, alcohol use
and condom use were not associated with either HIV-1
or HSV-2 infection status.
Multivariate analysis: risk factors for HSV-2 and HIV-1 and
effect of HSV-2 on HIV-1
Multivariate analysis using multilevel generalized linear
mixed effects models - with women nested in geographic
clusters - were fitted. All the variables that were found
to be significantly associated with HIV-1 and HSV-2 at
0.30 levels in the univariate analysis were included as
covariates in the multivariate analysis. The results of the
multivariate analyses are reported in Figures 1, 2.
The adjusted results in Figures 1, 2 indicate that older
women were more likely to have HSV-2 compared to
younger women. For example, the odds of having HSV-2
in a woman 40 years or older was 9.88 times higher than
that of woman between 20 and 24 years (OR=9.88; 95%,
CI: 6.01-16.23). The effects of religion, ethnicity, number
of sexual partners and female circumcision on HSV-2
were not significant. However, age at sexual onset was
significantly associated with HSV-2. Women who started
their sexual debut before 18 years were more likely to
have HSV-2 that those who began to have sex at 18 to
19 years or age 20 and older (OR=0.72, 95% CI=0.52-
0.99; OR=0.51, 95% CI=0.37-0.71). Testing positive for
other STIs (OR=1.67, 95% CI=1.15-2.43) and having
STI symptoms (OR=1.41, 95% CI=1.06-1.85) were
associated with a higher prevalence of HSV-2.
Women who tested positive for HSV-2 had a higher
prevalence of HIV-1. The odds of having HIV-1 in HSV-2
positive women were 2.72 times higher than that of
women who tested negative for HSV-2 (OR=2.72; 95%,
CI: 1.77-4.21). In contrast to HSV-2, HIV-1 prevalence did
not significantly vary by the age of the woman. However,
age at sexual debut was significantly associated with HIV-
1 as observed with HSV-2. Women who had first sex at
18 to 19 years or age 20 and older were less likely to have
HIV-1 than women who had first sex before age 18
(OR=0.49, 95% CI=0.31-0.81; OR=0.61, 95% CI=0.37-
0.95). Moreover, women who had two or more partners in
the previous three years (OR=2.09; 95% CI: 1.22-3.57)
were more likely to have HIV-1 compared with women
who had one partner. Furthermore, testing positive for
other STIs (OR=1.62, 95% CI=1.01-2.61) were associated
with high prevalence of HIV-1.
Table 1 Herpes simplex virus type-2 and HIV-1 prevalence by socio-demographic, high risk behavior, biological and
medical factors among women in Moshi district, northern Tanzania (Continued)
HSV-2 - <0.01
No - - 755 (60) 54 (35)
Yes - - 509 (40) 100 (65)
*Syphilis, Chlamydia, gonorrhea, trichomonas and mycoplasma genitalium.
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The prevalence of HSV-2 infection among all study par-
ticipants was 43%. The prevalence rate of HSV-2 among
the HIV-negative and HIV-positive women was 40% and
65%, respectively. These rates are comparable to the
rates reported in other studies from sub-Saharan Africa
[23]. We found 2.72 times odds of having HIV-1 in an
HSV-2 seropositive woman than in an HSV-2 seronega-
tive woman. Our finding is consistent with a previous
meta-analyses of cohort studies that showed that HSV-2
infection led to two to three times increase in risk of
acquiring HIV-1 [5,27,28]. Two recent cohort studies
from Uganda and Zimbabwe reported hazards ratios of
HIV-1 acquisition of 2.8 and 4.4 for prevalent HSV-2 in-
fection, respectively, and 4.6 and 8.6 for incident infec-
tion, respectively [29].
Consistent with other studies from the sub-region
[30,31], we found a direct association between HSV-2
and HIV-1 infections. Our finding of HSV-2 as a signifi-
cant predictor for HIV-1 infection coupled with findings
from other investigators that HSV-2 acquisition gener-
ally precedes HIV-1 seroconversion [30] support our
Figure 2 Risk factors for HIV-1 among women in Moshi district, northern Tanzania.
Figure 1 Risk factors for HSV-2 among women in Moshi district, northern Tanzania.
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the HIV-1 epidemic in sub-Saharan Africa. The interplay
between HIV-1 and HSV-2 infections is known to be bi-
directional and complex. From our study and that of
others, HSV-2 seems to serve as both a high-risk and
biological cofactor for HIV-1 acquisition.
HIV-1 and HSV-2 shared common high-risk sexual be-
havior factors such as early onset of sexual debut, and test-
ing positive for other STIs. Is it possible that the association
between HIV-1 acquisition and HSV-2 is confounded by
high-risk sexual behaviors placing individuals at risk for
both viruses? This concept is attractive and may help ex-
plain the inconsistent results of efficacy trials of HSV-2 sup-
pression for prevention of HIV acquisition. However, our
data will argue to the contrary. The higher prevalence of
H S V - 2a n di t sp r e d o m i n a n c ei no l d e rw o m e ns u g g e s tt h a t
HSV epidemic predates that of HIV. Moreover, it is well
known that infection with one STI may increase the prob-
ability of acquiring or transmitting another STI. These
could be the potential reasons for the high prevalence of
HIV-1 in our study among women who were HSV-2 sero-
positive. The increased risk of HSV-2 and HIV-1 associated
with an early age at first sex may be partly due to biological,
behavioral, and socio-economic predispositions [24].
HSV-2 may serve as a biological cofactor for HIV-1
acquisition. HSV-2 creates potential biological bridges
for HIV acquisition; by erosion of the epithelial barrier
through which HIV-1 can enter and by causing localized
inflammation that leads to the recruitment of new HIV-1
susceptible targets such as activated CD4+ T-cells and
macrophages that live in the sub- epithelium [32,33]. Fur-
thermore, some HSV-2 proteins have been reported to
directly interact in vitro with HIV-1 long terminal
repeat (LTR) region to up-regulate HIV-1 replication
through NF-κB activation [34]. The above biological phe-
nomena lead to increase HIV-1 viral load in plasma and
genital secretions of individuals with HIV-1 and HSV-2
co-infection during symptomatic and asymptomatic re-
activation of HSV-2 [16].
The present study has several strengths compared to
previous studies; it has a large sample size and used
laboratory-confirmed STIs in a population based sample.
Most studies of the prevalence of HSV-2 and its role as
a risk factor for HIV have been carried out in particular
groups that are not representative of the overall popula-
tion, such as STD or antenatal clinic attendees, blood
donors, or men who have sex with men [35]. However,
our study had some limitations. A strong case for causal-
ity cannot be made given the cross-sectional nature of
the study; however, our findings reiterate the need for
further research. Longitudinal studies, taking into con-
sideration the anti-HIV effect of acyclovir, are needed to
elucidate the nature of the relationship between HSV-2
and HIV-1 infections.
Conclusions
In conclusion, we found a significant association and
synergy between HSV-2 and HIV-1 infections among
study participants. HSV-2 may be a biological and risk
cofactor for HIV-1 acquisition. In resource-limited coun-
tries, where both infections are prevalent efforts at
symptomatic and diagnostic screening and treatment of
HSV-2 could be part of the preventive measures for
HIV-1. Furthermore, our study identified specific high-
risk behaviors – early onset of sexual debut, multiple
sexual partners and presence of other STIs – that could
be used in crafting messages for HIV-1 prevention
programs.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MG designed the study and analyzed the data. MG and EP wrote the article.
DH helped with the revision of the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
We thank the women of Moshi urban district of Tanzania for their
participation, Dr. Ulla Larsen the PI of the original study, and staff at the
National Bureau of Statistics in Tanzania for conducting the survey. The study
was supported by grants from the Harvard University Center for AIDS
Research (HU CFAR NIH/NAIDS P30-AI 060354) and EP is supported by grant
from the National Institute of Health (K08AI074404).
Author details
1Harvard Medical School and Ragon Institute of MGH, MIT and Harvard,
Boston, Massachusetts, USA.
2Department of Statistics, University of Akron,
Akron, Ohio, USA.
3Departments of Pediatrics and Pharmacology, Yale School
of Medicine, New Haven, Connecticut, USA.
Received: 24 July 2012 Accepted: 17 August 2012
Published: 21 August 2012
References
1. Looker KJ, Garnett GP, Schmid GP: An estimate of the global prevalence
and incidence of herpes simplex virus type 2 infection. Bull World Health
Organ 2008, 86(10):805–812, A.
2. Gwanzura L, McFarland W, Alexander D, Burke RL, Katzenstein D:
Association between human immunodeficiency virus and herpes
simplex virus type 2 seropositivity among male factory workers in
Zimbabwe. J Infect Dis 1998, 177(2):481–484.
3. Reynolds SJ, Risbud AR, Shepherd ME, Zenilman JM, Brookmeyer RS,
Paranjape RS, Divekar AD, Gangakhedkar RR, Ghate MV, Bollinger RC, et al:
Recent herpes simplex virus type 2 infection and the risk of human
immunodeficiency virus type 1 acquisition in India. J Infect Dis 2003,
187(10):1513–1521.
4. Todd J, Grosskurth H, Changalucha J, Obasi A, Mosha F, Balira R, Orroth K,
Hugonnet S, Pujades M, Ross D, et al: Risk factors influencing HIV infection
incidence in a rural African population: a nested case–control study.
J Infect Dis 2006, 193(3):458–466.
5. Glynn JR, Biraro S, Weiss HA: Herpes simplex virus type 2: a key role in HIV
incidence. AIDS 2009, 23(12):1595–1598.
6. Mbopi Keou FX, Gresenguet G, Mayaud P, Weiss HA, Gopal R, Brown DW,
Hayes RJ, Mabey DC, Belec L: Genital herpes simplex virus type 2
shedding is increased in HIV-infected women in Africa.
AIDS (London, England) 1999, 13(4):536–537.
7. Schacker T, Zeh J, Hu H, Shaughnessy M, Corey L: Changes in plasma
human immunodeficiency virus type 1 RNA associated with herpes
simplex virus reactivation and suppression. J Infect Dis 2002,
186(12):1718–1725.
Ghebremichael et al. BMC Research Notes 2012, 5:451 Page 6 of 7
http://www.biomedcentral.com/1756-0500/5/4518. Corey L, Wald A, Celum CL, Quinn TC: The effects of herpes simplex virus-
2 on HIV-1 acquisition and transmission: a review of two overlapping
epidemics. J Acquir Immune Defic Syndr 2004, 35(5):435–445.
9. Johnson RE, Nahmias AJ, Magder LS, Lee FK, Brooks CA, Snowden CB: A
seroepidemiologic survey of the prevalence of herpes simplex virus type
2 infection in the United States. N Engl J Med 1989, 321(1):7–12.
10. Seroprevalence of herpes simplex virus type 2 among persons aged
14–49 years--United States. MMWR Morb Mortal Wkly Rep 2005–2008,
59(15):456–459.
11. Abu-Raddad LJ, Magaret AS, Celum C, Wald A, Longini IM Jr, Self SG, Corey
L: Genital herpes has played a more important role than any other
sexually transmitted infection in driving HIV prevalence in Africa. PLoS
One 2008, 3(5):e2230.
12. Celum C, Levine R, Weaver M, Wald A: Genital herpes and human
immunodeficiency virus: double trouble. Bull World Health Organ 2004,
82(6):447–453.
13. Wald A, Corey L: How does herpes simplex virus type 2 influence human
immunodeficiency virus infection and pathogenesis? J Infect Dis 2003,
187(10):1509–1512.
14. Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, Mugo N, Mujugira A,
Baeten JM, Mullins JI, Hughes JP, et al: Acyclovir and transmission of HIV-1
from persons infected with HIV-1 and HSV-2. N Engl J Med 2010, 362
(5):427–439.
15. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O,
Kiwanuka N, Kigozi G, Kiddugavu M, Lutalo T, et al: Rates of HIV-1
transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda.
J Infect Dis 2005, 191(9):1403–1409.
16. Mbopi-Keou FX, Legoff J, Gresenguet G, Si-Mohamed A, Matta M, Mayaud P,
Andreoletti L, Malkin JE, Weiss H, Brown D, et al: Genital shedding of
herpes simplex virus-2 DNA and HIV-1 RNA and proviral DNA in HIV-1-
and herpes simplex virus-2-coinfected African women. J Acquir Immune
Defic Syndr 2003, 33(2):121–124.
17. Ouedraogo A, Nagot N, Vergne L, Konate I, Weiss HA, Defer MC, Foulongne
V, Sanon A, Andonaba JB, Segondy M, et al: Impact of suppressive herpes
therapy on genital HIV-1 RNA among women taking antiretroviral
therapy: a randomized controlled trial. AIDS 2006, 20(18):2305–2313.
18. Zuckerman RA, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, Zuniga R,
Magaret AS, Wald A, Corey L, Celum C: Herpes simplex virus (HSV)
suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels
in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-
controlled crossover trial. JI n f e c tD i s2007, 196(10):1500–1508.
19. Tanton C, Weiss HA, Rusizoka M, Legoff J, Changalucha J, Baisley K, Mugeye
K, Everett D, Belec L, Clayton TC, et al: Long-term impact of acyclovir
suppressive therapy on genital and plasma HIV RNA in Tanzanian
women: a randomized controlled trial. J Infect Dis 2010, 201(9):1285–1297.
20. Ludema C, Cole SR, Poole C, Chu H, Eron JJ: Meta-analysis of randomized
trials on the association of prophylactic acyclovir and HIV-1 viral load in
individuals coinfected with herpes simplex virus-2. AIDS 2011, 25
(10):1265–1269.
21. Lisco A, Vanpouille C, Tchesnokov EP, Grivel JC, Biancotto A, Brichacek B,
Elliott J, Fromentin E, Shattock R, Anton P, et al: Acyclovir is activated into
a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human
tissues. Cell Host Microbe 2008, 4(3):260–270.
22. Lisco A, Vanpouille C, Margolis L: A missed point in deciphering the viral
synergy between herpes simplex virus and HIV. Lancet Infect Dis 2009, 9
(9):522–523.
23. Nilsen A, Mwakagile D, Marsden H, Langeland N, Matre R, Haarr L:
Prevalence of, and risk factors for, HSV-2 antibodies in sexually
transmitted disease patients, healthy pregnant females, blood donors
and medical students in Tanzania and Norway. Epidemiol Infect 2005, 133
(5):915–925.
24. Ghebremichael M, Larsen U, Paintsil E: Association of age at first sex with
HIV-1, HSV-2, and other sexual transmitted infections among women in
northern Tanzania. Sex Transm Dis 2009, 36(9):570–576.
25. Rabe-Hesketh S, Skrondal A: Classical latent variable models for medical
research. Stat Methods Med Res 2008, 17(1):5–32.
26. Schabenberger O: Growing up fast: SAS 9.2 enhancements to the GLIMMIX
procedure. Orlando, FL: SAS Global Forum; 2007.
27. Wald A, Link K: Risk of human immunodeficiency virus infection in
herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect
Dis 2002, 185(1):45–52.
28. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ: Herpes
simplex virus 2 infection increases HIV acquisition in men and women:
systematic review and meta-analysis of longitudinal studies. AIDS 2006,
20(1):73–83.
29. Brown JM, Wald A, Hubbard A, Rungruengthanakit K, Chipato T, Rugpao S,
Mmiro F, Celentano DD, Salata RS, Morrison CS, et al: Incident and
prevalent herpes simplex virus type 2 infection increases risk of HIV
acquisition among women in Uganda and Zimbabwe. AIDS 2007, 21
(12):1515–1523.
30. del Mar Pujades Rodriguez M, Obasi A, Mosha F, Todd J, Brown D,
Changalucha J, Mabey D, Ross D, Grosskurth H, Hayes R: Herpes simplex
virus type 2 infection increases HIV incidence: a prospective study in
rural Tanzania. AIDS 2002, 16(3):451–462.
31. Kapiga SH, Bang H, Spiegelman D, Msamanga GI, Coley J, Hunter DJ, Fawzi WW:
Correlates of plasma HIV-1 RNA viral load among HIV-1-seropositive women
in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr 2002, 30(3):316–323.
32. Cunningham AL, Turner RR, Miller AC, Para MF, Merigan TC: Evolution of
recurrent herpes simplex lesions, An immunohistologic study.
J Clin Invest 1985, 75(1):226–233.
33. Koelle DM, Abbo H, Peck A, Ziegweid K, Corey L: Direct recovery of herpes
simplex virus (HSV)-specific T lymphocyte clones from recurrent genital
HSV-2 lesions. J Infect Dis 1994, 169(5):956–961.
34. Margolis DM, Rabson AB, Straus SE, Ostrove JM: Transactivation of the HIV-
1 LTR by HSV-1 immediate-early genes. Virology 1992, 186(2):788–791.
35. Ades AE, Peckham CS, Dale GE, Best JM, Jeansson S: Prevalence of
antibodies to herpes simplex virus types 1 and 2 in pregnant women,
and estimated rates of infection. J Epidemiol Community Health 1989,
43(1):53–60.
doi:10.1186/1756-0500-5-451
Cite this article as: Ghebremichael et al.: Deciphering the epidemic
synergy of herpes simplex virus type 2 (HSV-2) on human
immunodeficiency virus type 1 (HIV-1) infection among women in sub-
Saharan Africa. BMC Research Notes 2012 5:451.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ghebremichael et al. BMC Research Notes 2012, 5:451 Page 7 of 7
http://www.biomedcentral.com/1756-0500/5/451